Bupropion SR for the treatment of smokeless tobacco use

Drug and Alcohol Dependence

Volumn 90, Issue 1, 2007, Pages 56-63

  Dale, Lowell C ^a   Ebbert, Jon O ^a   Glover, Elbert D ^b   Croghan, Ivana T ^a   Schroeder, Darrell R ^a   Severson, Herbert H ^c   Hurt, Richard D ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c OREGON RESEARCH INSTITUTE   (United States)

Author keywords

Bupropion; Smokeless; Tobacco; Tobacco use cessation

Indexed keywords

AMFEBUTAMONE;

ABSTINENCE; ADULT; AGED; AORTA STENOSIS; APPENDICITIS; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HEART INFARCTION; HERNIA; HUMAN; IRRITABILITY; KIDNEY INJURY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SIDE EFFECT; SLEEP DISORDER; SMOKELESS TOBACCO; SMOKING CESSATION; SORE THROAT; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; COTININE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SUBSTANCE ABUSE DETECTION; TOBACCO USE DISORDER; TOBACCO, SMOKELESS;

NICOTIANA TABACUM;

EID: 34250641512     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.02.008     Document Type: Article

References (40)

1. Benowitz N.L., Ahijevych K., Hall S., Hansson A., Henningfield J., Hurt R.D., Jacob P.I., Jarvis M.J., LeHouezec J., Lichtenstein E., Tsoh J., and Velicer W. Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 4 (2002) 149-159
2. Boyle R.G., Jensen J., Hatsukami D.K., and Severson H.H. Measuring dependence in smokeless tobacco users. Addict. Behav. 20 (1995) 443-450
3. Dale L.C., Ebbert J.O., Schroeder D.R., Croghan I.T., Rasmussen D.F., Trautman J.A., Cox L.S., and Hurt R.D. Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study. Nicotine Tob. Res. 4 (2002) 267-274
4. Ebbert J.O., Dale L.C., Patten C.A., et al. Effect of high dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob. Res. 9 1 (2007) 43-52
5. Ebbert J.O., Klinkhammer M.D., Stevens S.R., Rowland L.C., Offord K.P., Ames S.C., and Dale L.C. A survey of characteristics of smokeless tobacco users in a treatment program. Am. J. Health Behav. 29 (2005) 25-35
6. Ebbert, J.O., Rowland, L.C., Montori, V., Vickers, K.S., Erwin, P.C., Dale, L.C., Stead, L.F., 2004. Interventions for smokeless tobacco use cessation. Cochrane Database Syst. Rev., CD004306.
7. Ebbert J.O., Rowland L.C., Montori V.M., Vickers K.S., Erwin P.J., and Dale L.C. Treatments for spit tobacco use: a quantitative systematic review. Addiction 98 (2003) 569-583
8. Ernster V.L., Grady D.G., Greene J.C., Walsh M., Robertson P., Daniels T.E., Benowitz N., Siegel D., Gerbert B., and Hauck W.W. Smokeless tobacco use and health effects among baseball players. JAMA 264 (1990) 218-224
9. Glover E., Glover P., Sullivan C., Cerullo C., and Hobbs G. A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation. Am. J. Health Behav. 26 (2002) 386-393
10. Goodman M.T., Morgenstern H., and Wynder E.L. A case-control study of factors affecting the development of renal cell cancer. Am. J. Epidemiol. 124 (1986) 926-941
11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
12. Hatsukami D., Jensen J., Allen S., Grillo M., and Bliss R. Effects of behavioral and pharmacological treatment on smokeless tobacco users. J. Consult. Clin. Psychol. 64 (1996) 153-161
13. Hatsukami D.K., Grillo M., Boyle R., Allen S., Jensen J., Bliss R., and Brown S. Treatment of spit tobacco users with transdermal nicotine system and mint snuff. J. Consult. Clin. Psychol. 68 (2000) 241-249
14. Hayford K.E., Patten C.A., Rummans T.A., Schroeder D.R., Offord K.P., Croghan I.T., Glover E.D., Sachs D.P., and Hurt R.D. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. J. Psychiatry 174 (1999) 173-178
15. Henley S.J., Thun M.J., Connell C., and Calle E.E. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 16 (2005) 347-358
16. Hughes J.R. Errors in using tobacco withdrawal scale [letter to editor]. Tob. Contr. 7 (1998) 92-93
17. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 43 (1986) 289-294
18. Hughes, J.R., Stead, L.F., Lancaster, T., 2002. Antidepressants for smoking cessation. Cochrane Database Syst. Rev., CD000031.
19. Hurt R., Sachs D., Glover E., Offord K., Johnston J., Dale L., Khayrallah M., Schroeder D., Glover P., Sullivan C., Croghan I., and Sullivan P. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337 (1997) 1195-1202
20. Jorenby D.E., Leischow S.J., Nides M., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., and Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340 (1999) 685-691
21. Liang K., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 3-22
22. Little S.J., Stevens V.J., LaChance P.A., Severson H.H., Bartley M.H., Lichtenstein E., and Leben J.R. Smokeless tobacco habits and oral mucosal lesions in dental patients. J. Public Health Dent. 52 (1992) 269-276
23. Martin G.C., Brown J.P., Eifler C.W., and Houston G.D. Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J. Am. Dent. Assoc. 130 (1999) 945-954
24. Mattson M.E., and Winn D.M. Smokeless tobacco: association with increased cancer risk. NCI Monogr. (1989) 13-16
25. McNeill A. Harm reduction. Br. Med. J. 328 (2004) 885-887
26. Moyer T.P., Charlson J.R., Enger R.J., Dale L.C., Ebbert J.O., Schroeder D.R., and Hurt R.D. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin. Chem. 48 (2002) 1460-1471
27. Muscat J.E., Hoffmann D., and Wynder E.L. The epidemiology of renal cell carcinoma. A second look. Cancer 75 (1995) 2552-2557
28. Muscat J.E., Stellman S.D., Hoffmann D., and Wynder E.L. Smoking and pancreatic cancer in men and women. Cancer Epidemiol. Biomark. Prev. 6 (1997) 15-19
29. National Institute of Health. National Institutes of Health State-of-the-Science conference statement: tobacco use: prevention, cessation, and control. Ann. Intern. Med. 145 (2006) 839-844
30. Robins L.N., Helzer J.E., Croughan J., and Ratcliff K.S. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch. Gen. Psychiatry 38 (1981) 381-389
31. Severson, H., 1992. Enough snuff: ST Cessation from the behavioral, clinical, and public health perspectives. NIH Publication No. 93-3461.
32. Severson H.H. What have we learned from 20 years of research on smokeless tobacco cessation?. Am. J. Med. Sci. 326 (2003) 206-211
33. Skinner H.A. Assessment of substance abuse: drug abuse screening test (DAST). In: Carson-DeWitt R. (Ed). Encyclopedia of Drugs, Alcohol, & Addictive Behaviors (2001), Macmillan Reference, Durham, NC
34. Stockwell H.G., and Lyman G.H. Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. Head. Neck. Surg. 9 (1986) 104-110
35. Substance Abuse and Mental Health Services Administration, 2006. Results from the 2005 National Survey on Drug Use and Health: Detailed Tables. http://www.oas.samhsa.gov/NSDUH/2k5NSDUH/tabs/TOC.htm (Accessed: December 1 2006).
36. Swenson W.M., and Morse R.M. The use of a self-administered alcoholism screening test (SAAST) in a medical center. Mayo Clin. Proc. 50 (1975) 204-208
37. Teneggi V., Tiffany S.T., Squassante L., Milleri S., Ziviani L., and Bye A. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology (Berl.) 164 (2002) 177-187
38. Teneggi V., Tiffany S.T., Squassante L., Milleri S., Ziviani L., and Bye A. Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology (Berl.) 183 (2005) 1-12
39. Teo K.K., Ounpuu S., Hawken S., Pandey M.R., Valentin V., Hunt D., Diaz R., Rashed W., Freeman R., Jiang L., Zhang X., and Yusuf S. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368 (2006) 647-658
40. Tomar S.L., Winn D.M., Swango P.A., Giovino G.A., and Kleinman D.V. Oral mucosal smokeless tobacco lesions among adolescents in the United States. J. Dent. Res. 76 (1997) 1277-1286